<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35908647</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2472-6311</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>SLAS technology</Title><ISOAbbreviation>SLAS Technol</ISOAbbreviation></Journal><ArticleTitle>Inflammatory mediators, lipoproteins and apolipoproteins in early diagnosis of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>327</StartPage><EndPage>334</EndPage><MedlinePgn>327-334</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.slast.2022.07.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2472-6303(22)05165-2</ELocationID><Abstract><AbstractText>There is currently no diagnostic or prognostic biomarker available in clinical practice for Amyotrophic Lateral Sclerosis (ALS). The objective of this study was to monitor a combination of various inflammatory markers, lipids, and apolipoproteins alterations in ALS patients at the time of diagnosis, to assess their role as early diagnostic or prognostic biomarker candidates. C-reactive protein, orosomucoid, prealbumin, calprotectin, lipids and apoliproteins were determined in the blood of all subjects (25 ALS patients, 23 controls) as routinely performed in our laboratory. Inflammatory mediators were evaluated by a bead-based multiplex assay. A two-step approach was used for each analytical strategy: univariate analysis followed by multivariate analysis. Eight features were significantly different between ALS patients and controls, sometimes with important fold changes. The supervised Partial least Squares Discriminant Analysis separated ALS and controls with great accuracy (94 %) and the permutation test was significant (p &lt; 0.01), ensuring the robustness of the model. The prediction model leads to a mean sensitivity and specificity of 90 (+/- 10) and 78 (+/- 10) %, respectively, with a mean predictive positive value and negative predictive value of 80 (+/- 8.9) and 89 (+/- 11.8) %, respectively. However, the models did not discriminate subgroups of ALS patients based on ALS characteristics. This study highlights the usefulness of evaluating a combination of multiple pathways rather than focusing on a single target. These promising results suggest the need for the longitudinal monitoring of these candidates to determine their role in disease evolution.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alarcan</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratoire de biochimie et biologie mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France. Electronic address: hugo.alarcan@univ-tours.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berthet</LastName><ForeName>M&#xe9;lanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratoire de biochimie et biologie mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suire</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratoire de biochimie, CHRU Trousseau, avenue de la R&#xe9;publique, 37170 Chambray-l&#xe8;s-Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colas</LastName><ForeName>Corentin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de biochimie et biologie mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Lo&#xef;c</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>UMR1100 &#xab; Infection respiratoire &amp; Immunit&#xe9; &#xbb;, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paget</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>UMR1100 &#xab; Infection respiratoire &amp; Immunit&#xe9; &#xbb;, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benz-de Bretagne</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratoire de biochimie, CHRU Trousseau, avenue de la R&#xe9;publique, 37170 Chambray-l&#xe8;s-Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piver</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratoire de biochimie, CHRU Trousseau, avenue de la R&#xe9;publique, 37170 Chambray-l&#xe8;s-Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratoire de biochimie et biologie mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France; UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de biochimie et biologie mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France; UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France; Service de neurologie, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratoire de biochimie et biologie mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France; UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>SLAS Technol</MedlineTA><NlmUniqueID>101697564</NlmUniqueID><ISSNLinking>2472-6303</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001053">Apolipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039841">Leukocyte L1 Antigen Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009961">Orosomucoid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011228">Prealbumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001053" MajorTopicYN="N">Apolipoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039841" MajorTopicYN="N">Leukocyte L1 Antigen Complex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009961" MajorTopicYN="N">Orosomucoid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011228" MajorTopicYN="N">Prealbumin</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Apolipoproteins</Keyword><Keyword MajorTopicYN="N">Inflammatory mediators</Keyword><Keyword MajorTopicYN="N">Lipids</Keyword><Keyword MajorTopicYN="N">PLS-DA</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>31</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35908647</ArticleId><ArticleId IdType="doi">10.1016/j.slast.2022.07.003</ArticleId><ArticleId IdType="pii">S2472-6303(22)05165-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>